Open access
Prognostic Stratification in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line Androgen Receptor Pathway Inhibitor–Based Combination Therapy
Keiichiro Miyajima
T. Yanagisawa
Wataru Fukuokaya
Ryoko Sakakibara
Naoki Uchida
Marcin Miszczyk
Shota Inoue
A. Matsukawa
F. Urabe
K. Mori
N. Fujita
Shintaro Narita
S. Hatakeyama
T. Habuchi
S. Shariat
Takahiro Kimura
Medicine
Abstract
We aimed to stratify clinical risk among patients with high‐volume metastatic hormone‐sensitive prostate cancer (mHSPC) treated with first‐line androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT).